Tenon Medical, Inc. (TNON)

Over the past six months, TENON Medical's stock price has experienced significant fluctuations. As of January 6, 2026, the share price was $1.00, representing a 52.49% decline from $2.10 on January 7, 2025. The stock price decreased by 47.28% over the last 12 months and 14.91% in the past month. In November 2025, TENON Medical announced the pricing of an at-the-market private investment in public equity (PIPE) financing, raising $2.85 million. In December 2025, the company announced the completion of initial cases with its new SImmetry+ SI Joint Fusion System. In March 2025, the stock saw a significant surge following the European Patent Office's approval of its Catamaran SI Joint Fixation Device and FDA clearance for expanded use of its Catamaran SI Joint Fusion System. In January 2025, the stock hit a new 52-week low of $1.66, but the company regained Nasdaq compliance after addressing issues related to board independence, minimum bid price, public float, and stockholders' equity through equity financing transactions and secured three new U.S. patents for its Catamaran SI Joint Fusion System.

Historically, buying TNON stock in October has shown the highest probability of a positive return (66.67%), while March has exhibited the lowest probability (0.00%), suggesting potential seasonal patterns in investor interest or market activity related to the company's stock.

TENON Medical, Inc. (TNON) is a medical device company focused on developing implants for treating severe lower back pain in the United States. The company operates within the Healthcare sector, specifically in the Medical Devices and Medical/Dental Instruments industries. TENON Medical's primary product is the Catamaran SI Joint Fusion System, which offers a minimally invasive approach to the sacroiliac (SI) joint using a single, robust titanium implant. The Catamaran Fixation Device stabilizes and transfixes the SI Joint along its longitudinal axis. The surgical approach avoids critical neural and vascular structures while targeting strong cortical bone. The Catamaran System resists vertical shear and rotation of the implanted joint, facilitating eventual fusion. The company also utilizes proprietary two-dimensional (2D) placement protocols and three-dimensional (3D) navigation techniques for spine surgery. TENON Medical focuses on three commercial opportunities within the SI Joint market: primary SI Joint procedures, revision procedures for failed SI Joint implants, and SI Joint fusion as an adjunct to spinal fusion constructs.

TENON Medical, Inc. primarily engages in the development of implants for the treatment of severe lower back pain in the United States. The company is headquartered in Los Gatos, California.

In the past year, TENON Medical's brand reputation has likely been positively influenced by the European Patent Office's approval of the Catamaran SI Joint Fixation Device and the FDA's clearance for expanded use of the Catamaran SI Joint Fusion System. Securing three new U.S. patents for its Catamaran SI Joint Fusion System further strengthens its intellectual property portfolio and innovative standing. The company also regained Nasdaq compliance status, which positively impacts its standing in the financial markets.

TENON Medical, Inc. has 19 institutional owners and shareholders holding a total of 284,696 shares, representing 22.74% of the stock. Major institutional shareholders include Vanguard Group Inc, Geode Capital Management, Llc, SBI Securities Co., Ltd., XTX Topco Ltd, and Citadel Advisors Llc. Individual insiders hold 7.14% of the shares, while private companies hold 3.17%. SiVantage, Inc. is listed as a major shareholder with 9.55% of equities.